Literature DB >> 16586534

Interleukin-10 and chronic liver disease.

Li-Juan Zhang1, Xiao-Zhong Wang.   

Abstract

Interleukin (IL)-10 is an important immunoregulatory cytokine produced by many cell populations. Numerous investigations suggest that IL-10 plays a major role in chronic liver diseases. IL-10 gene polymorphisms are possibly associated with liver disease susceptibility or severity. Recombinant human IL-10 has been produced and is currently tested in clinical trials. These trials may give new insights into the immunobiology of IL-10 and suggest that the IL-10/IL-10 receptor system may become a new therapeutic target.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16586534      PMCID： PMC4124340          DOI： 10.3748/wjg.v12.i11.1681

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN： 1007-9327            Impact factor:   5.742


  70 in total

1.  Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect.

Authors:  David R Nelson; Zhengkun Tu; Consuelo Soldevila-Pico; Manal Abdelmalek; Haizhen Zhu; Yi Ling Xu; Roniel Cabrera; Chen Liu; Gary L Davis
Journal:  Hepatology       Date:  2003-10       Impact factor: 17.425

Review 2.  Current status and prospects of studies on human genetic alleles associated with hepatitis B virus infection.

Authors:  Fu-Sheng Wang
Journal:  World J Gastroenterol       Date:  2003-04       Impact factor: 5.742

3.  Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules.

Authors:  F Y Yue; R Dummer; R Geertsen; G Hofbauer; E Laine; S Manolio; G Burg
Journal:  Int J Cancer       Date:  1997-05-16       Impact factor: 7.396

4.  Interleukin 10 haplotype associated with increased risk of hepatocellular carcinoma.

Authors:  Hyoung Doo Shin; Byung Lae Park; Lyoung Hyo Kim; Ji Hyun Jung; Jun Yeon Kim; Jung Hwan Yoon; Yoon Jun Kim; Hyo-Suk Lee
Journal:  Hum Mol Genet       Date:  2003-04-15       Impact factor: 6.150

5.  Anti-IL-10 therapeutic strategy using the immunomodulator AS101 in protecting mice from sepsis-induced death: dependence on timing of immunomodulating intervention.

Authors:  Yona Kalechman; Uzi Gafter; Rivka Gal; Galit Rushkin; Donghong Yan; Michael Albeck; Benjamin Sredni
Journal:  J Immunol       Date:  2002-07-01       Impact factor: 5.422

6.  IL-10 promoter polymorphisms influence disease severity and course in psoriasis.

Authors:  K Kingo; S Kõks; H Silm; E Vasar
Journal:  Genes Immun       Date:  2003-09       Impact factor: 2.676

Review 7.  Modulation of liver injury by interleukin-10.

Authors:  H Louis; O Le Moine; M Goldman; J Devière
Journal:  Acta Gastroenterol Belg       Date:  2003 Jan-Mar       Impact factor: 1.316

8.  Effects of transmitters and interleukin-10 on rat hepatic fibrosis induced by CCl4.

Authors:  Xiao-Zhong Wang; Li-Juan Zhang; Dan Li; Yue-Hong Huang; Zhi-Xin Chen; Bin Li
Journal:  World J Gastroenterol       Date:  2003-03       Impact factor: 5.742

9.  Influence of interleukin-10 gene promoter polymorphisms on disease progression in patients chronically infected with hepatitis B virus.

Authors:  Seiji Miyazoe; Keisuke Hamasaki; Keisuke Nakata; Yuji Kajiya; Kayo Kitajima; Kazuhiko Nakao; Manabu Daikoku; Hiroshi Yatsuhashi; Michiaki Koga; Michitami Yano; Katsumi Eguchi
Journal:  Am J Gastroenterol       Date:  2002-08       Impact factor: 10.864

10.  Expression of insulin-like growth factor 1 and insulin-like growth factor 1 receptor and its intervention by interleukin-10 in experimental hepatic fibrosis.

Authors:  Xiao-Zhong Wang; Zhi-Xin Chen; Li-Juan Zhang; Yun-Xin Chen; Dan Li; Feng-Lin Chen; Yue-Hong Huang
Journal:  World J Gastroenterol       Date:  2003-06       Impact factor: 5.742
View more
  17 in total

1.  Hepatoprotective effect of ulinastatin in a rat model of major hepatectomy after obstructive jaundice.

Authors:  Xun Li; Jing Li; Yang-Jie Ou; Xiao-Xu Zhu; Xiao-Yu Yin; Yun-Xiao Zhu; Di Tang
Journal:  Dig Dis Sci       Date:  2015-02-03       Impact factor: 3.199

2.  Transforming growth factor-β and toll-like receptor-4 polymorphisms are not associated with fibrosis in haemochromatosis.

Authors:  Marnie J Wood; Lawrie W Powell; Jeannette L Dixon; V Nathan Subramaniam; Grant A Ramm
Journal:  World J Gastroenterol       Date:  2013-12-28       Impact factor: 5.742

Review 3.  Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease.

Authors:  Shankar Subramanian Iyer; Gehong Cheng
Journal:  Crit Rev Immunol       Date:  2012       Impact factor: 2.214

4.  Combined effect of pro- and anti-inflammatory cytokine gene polymorphisms on susceptibility to liver cirrhosis in Tunisian HCV-infected patients.

Authors:  Nadia Bouzgarrou; Elham Hassen; Olfa Bahri; Sallouha Gabbouj; Nabil Ben Mami; Henda Triki; Lotfi Chouchane
Journal:  Hepatol Int       Date:  2011-02-08       Impact factor: 6.047

5.  NKT cells act through third party bone marrow-derived cells to suppress NK cell activity in the liver and exacerbate hepatic melanoma metastases.

Authors:  Leila Sadegh; Peter W Chen; Joseph R Brown; Zhiqiang Han; Jerry Y Niederkorn
Journal:  Int J Cancer       Date:  2015-02-27       Impact factor: 7.396

6.  Effects of interleukin-10 gene deficiency on hepatic biochemical metabolism in mice.

Authors:  Jing Du; Jian Zhang; Dexue Zou; Liang Ye; G George Chen; Chao Yang
Journal:  Clin Exp Med       Date:  2014-06-13       Impact factor: 3.984

7.  The balance of type 1 and type 2 immune responses in the contexts of hepatitis B infection and hepatitis D infection.

Authors:  Elizabeth C Townsend; Grace Y Zhang; Rabab Ali; Marian Firke; Mi Sun Moon; Ma Ai Thanda Han; Benjamin Fram; Jeffrey S Glenn; David E Kleiner; Christopher Koh; Theo Heller
Journal:  J Gastroenterol Hepatol       Date:  2019-02-25       Impact factor: 4.029

8.  MCLR-elicited hepatic fibrosis and carcinogenic gene expression changes persist in rats with diet-induced nonalcoholic steatohepatitis through a 4-week recovery period.

Authors:  Tarana Arman; J Allen Baron; Katherine D Lynch; Laura A White; Johnny Aldan; John D Clarke
Journal:  Toxicology       Date:  2021-11-02       Impact factor: 4.221

9.  Efficacy of Tumor Necrosis Factor and Interleukin-10 Analysis in the Follow-up of Nonalcoholic Fatty Liver Disease Progression.

Authors:  Walid E Zahran; Kholoud A Salah El-Dien; Philip G Kamel; Ahmed Shawky El-Sawaby
Journal:  Indian J Clin Biochem       Date:  2012-07-14

10.  Immunologic Predictors of Liver Transplantation Outcomes in HIV-HCV Co-Infected Persons.

Authors:  Ashwin Balagopal; Burc Barin; Jeffrey Quinn; Rodney Rogers; Mark S Sulkowski; Peter G Stock
Journal:  PLoS One       Date:  2015-08-27       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.